Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus
© 2021. The Author(s)..
PURPOSE: To explore the efficacy and safety of using radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC) adjacent to the second hepatic hilus.
METHODS: Between February 2011 and June 2013, 17 patients with HCC underwent combination therapy of TACE and RFA under DSA and CT guidance at our institution. The 17 patients had a total of 23 hepatic tumors, 17 of which were adjacent to the second hepatic hilus.
RESULTS: TACE combined with RFA was performed successfully in all 17 patients with no mortalities or major morbidities. During the 1-month follow-up, tumors of 15 patients (88.2%) were completely ablated after one therapy session and 2 patients had detectable tumor residue. During the follow-up time period (range 6-52 months), local tumor progression developed in 1 patient (1/17, 5.9%) and both local tumor progression and new tumors appeared in 1 patient (1/17, 5.9%). Also, new tumors developed in the untreated portions of the liver in 8 patients (8/17, 47.1%). No distant metastasis was found. Of the 17 patients, 6 (35.3%) died due to tumor progression (3/17, 17.6%), liver failure (2/17, 11.8%), or massive hemorrhage of the gastrointestinal tract (1/17, 5.9%). The overall survival rates were 94.1% (16/17), 82.4% (14/17), and 61.8% (11/17) at 12, 18, and 24 months, respectively, and the median survival time was 25 months (95% CI 18-27).
CONCLUSION: Treatment using combination of TACE and RFA is an effective and safe therapeutic strategy for treating HCC with tumor(s) adjacent to the second hepatic hilus.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:47 |
|---|---|
| Enthalten in: |
Abdominal radiology (New York) - 47(2022), 1 vom: 21. Jan., Seite 423-430 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Meng-Li [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Hepatocellular carcinoma |
|---|
| Anmerkungen: |
Date Completed 08.03.2022 Date Revised 30.04.2022 published: Print-Electronic ErratumIn: Abdom Radiol (NY). 2022 Feb 7;:. - PMID 35129634 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00261-021-03304-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331768100 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331768100 | ||
| 003 | DE-627 | ||
| 005 | 20231225214204.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00261-021-03304-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331768100 | ||
| 035 | |a (NLM)34635940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Meng-Li |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Radiofrequency ablation combined with transarterial chemoembolization in treatment of hepatocellular carcinoma adjacent to the second hepatic hilus |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2022 | ||
| 500 | |a Date Revised 30.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Abdom Radiol (NY). 2022 Feb 7;:. - PMID 35129634 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a PURPOSE: To explore the efficacy and safety of using radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) for treating hepatocellular carcinoma (HCC) adjacent to the second hepatic hilus | ||
| 520 | |a METHODS: Between February 2011 and June 2013, 17 patients with HCC underwent combination therapy of TACE and RFA under DSA and CT guidance at our institution. The 17 patients had a total of 23 hepatic tumors, 17 of which were adjacent to the second hepatic hilus | ||
| 520 | |a RESULTS: TACE combined with RFA was performed successfully in all 17 patients with no mortalities or major morbidities. During the 1-month follow-up, tumors of 15 patients (88.2%) were completely ablated after one therapy session and 2 patients had detectable tumor residue. During the follow-up time period (range 6-52 months), local tumor progression developed in 1 patient (1/17, 5.9%) and both local tumor progression and new tumors appeared in 1 patient (1/17, 5.9%). Also, new tumors developed in the untreated portions of the liver in 8 patients (8/17, 47.1%). No distant metastasis was found. Of the 17 patients, 6 (35.3%) died due to tumor progression (3/17, 17.6%), liver failure (2/17, 11.8%), or massive hemorrhage of the gastrointestinal tract (1/17, 5.9%). The overall survival rates were 94.1% (16/17), 82.4% (14/17), and 61.8% (11/17) at 12, 18, and 24 months, respectively, and the median survival time was 25 months (95% CI 18-27) | ||
| 520 | |a CONCLUSION: Treatment using combination of TACE and RFA is an effective and safe therapeutic strategy for treating HCC with tumor(s) adjacent to the second hepatic hilus | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Hepatocellular carcinoma | |
| 650 | 4 | |a Radiofrequency ablation (RFA) | |
| 650 | 4 | |a Second hepatic hilus | |
| 650 | 4 | |a Transarterial chemoembolization (TACE) | |
| 700 | 1 | |a Li, Hai-Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Chen-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jung-Hoon |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Hong-Tao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Abdominal radiology (New York) |d 2016 |g 47(2022), 1 vom: 21. Jan., Seite 423-430 |w (DE-627)NLM256750947 |x 2366-0058 |7 nnns |
| 773 | 1 | 8 | |g volume:47 |g year:2022 |g number:1 |g day:21 |g month:01 |g pages:423-430 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00261-021-03304-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 47 |j 2022 |e 1 |b 21 |c 01 |h 423-430 | ||